gemtuzumab ozogamicin

DAGO2 (daunorubicin+cytarabine+fractionated gemtuzumab) outperforms CPX‑351 in older adults with non‑adverse‑risk AML: insights from NCRI AML18

In NCRI AML18 (n=439, median age 68), DAGO2 produced higher early CR/MRD‑negative rates and superior 3‑year EFS and OS versus CPX‑351 in older adults without adverse‑risk cytogenetics; survival differences persisted across key subgroups inc

Sustained Remission in Acute Promyelocytic Leukemia with ATO-ATRA and Gemtuzumab Ozogamicin: Long-Term Phase 2 Outcomes